cilostazol Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
644 73963-72-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • OPC 13013
  • cilostazol
  • cilostazole
  • pletal
  • OPC-13013
A quinoline and tetrazole derivative that acts as a phosphodiesterase type 3 inhibitor, with anti-platelet and vasodilating activity. It is used in the treatment of PERIPHERAL VASCULAR DISEASES; ISCHEMIC HEART DISEASE; and in the prevention of stroke.
  • Molecular weight: 369.47
  • Formula: C20H27N5O2
  • CLOGP: 3.53
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 1
  • TPSA: 81.93
  • ALOGS: -4.06
  • ROTB: 7

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.20 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.00 mg/mL Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 7.73 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
Jan. 15, 1999 FDA OTSUKA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaemia 94.30 38.77 35 421 34757 2322872
Ventricular fibrillation 57.45 38.77 13 443 2188 2355441
Cardiac failure 47.07 38.77 16 440 12078 2345551
Cerebral haemorrhage 45.62 38.77 13 443 5491 2352138

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cerebral infarction 112.48 35.32 33 791 5176 1740781
Tachycardia 90.95 35.32 35 789 12593 1733364
Atrial fibrillation 71.45 35.32 31 793 15080 1730877
Interstitial lung disease 63.06 35.32 25 799 9671 1736286
Haemorrhage subcutaneous 62.21 35.32 13 811 494 1745463
Cerebral haemorrhage 62.03 35.32 22 802 6255 1739702
Palpitations 60.27 35.32 22 802 6792 1739165
Melaena 54.28 35.32 19 805 5191 1740766
Agranulocytosis 52.97 35.32 17 807 3559 1742398
Haematochezia 51.42 35.32 18 806 4914 1741043
Gastrointestinal haemorrhage 50.66 35.32 24 800 14243 1731714
Cardiac failure 50.33 35.32 23 801 12579 1733378
Hypotension 49.08 35.32 30 794 29624 1716333
Thrombosis in device 48.94 35.32 12 812 939 1745018
Shock haemorrhagic 48.93 35.32 13 811 1403 1744554
Disseminated intravascular coagulation 48.72 35.32 16 808 3598 1742359
Gastric ulcer haemorrhage 48.36 35.32 12 812 987 1744970
Condition aggravated 47.19 35.32 26 798 21124 1724833
Hepatic function abnormal 45.10 35.32 18 806 7056 1738901
Acute kidney injury 42.17 35.32 29 795 34915 1711042
Anaemia 41.68 35.32 27 797 29430 1716527
Peripheral arterial occlusive disease 40.58 35.32 10 814 798 1745159
Pyrexia 39.08 35.32 31 793 46369 1699588
Acute myocardial infarction 38.47 35.32 17 807 8570 1737387
Drug interaction 38.00 35.32 25 799 27933 1718024

Pharmacologic Action:

SourceCodeDescription
ATC B01AC23 BLOOD AND BLOOD FORMING ORGANS
ANTITHROMBOTIC AGENTS
ANTITHROMBOTIC AGENTS
Platelet aggregation inhibitors excl. heparin
FDA EPC N0000175598 Phosphodiesterase 3 Inhibitor
MeSH PA D018927 Anti-Asthmatic Agents
MeSH PA D001993 Bronchodilator Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D005343 Fibrinolytic Agents
MeSH PA D006401 Hematologic Agents
MeSH PA D018696 Neuroprotective Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D058987 Phosphodiesterase 3 Inhibitors
MeSH PA D010726 Phosphodiesterase Inhibitors
MeSH PA D010975 Platelet Aggregation Inhibitors
MeSH PA D020011 Protective Agents
MeSH PA D019141 Respiratory System Agents
CHEBI has role CHEBI:50249 anticoagulant
CHEBI has role CHEBI:63726 neuroprotective agent
CHEBI has role CHEBI:35523 bronchodilator agent
CHEBI has role CHEBI:35620 vasodilator agent
CHEBI has role CHEBI:48676 fibrin modulating drug
CHEBI has role CHEBI:50427 platelet aggregation inhibitor
MeSH PA D014665 Vasodilator Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Intermittent claudication indication 63491006 DOID:3669
Chronic heart failure contraindication 48447003
Kidney disease contraindication 90708001 DOID:557
Disease of liver contraindication 235856003 DOID:409

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
cGMP-inhibited 3',5'-cyclic phosphodiesterase A Enzyme INHIBITOR IC50 6.70 IUPHAR CHEMBL
Cytochrome P450 2C9 Enzyme IC50 5 DRUG MATRIX
cGMP-inhibited 3',5'-cyclic phosphodiesterase B Enzyme INHIBITOR IC50 6.42 IUPHAR

External reference:

IDSource
D000077407 MESH_DESCRIPTOR_UI
4021153 VUID
N0000148605 NUI
C0055729 UMLSCUI
D01896 KEGG_DRUG
395239000 SNOMEDCT_US
4021153 VANDF
60734 MMSL
007339 NDDF
d04382 MMSL
7889 MMSL
21107 RXNORM
116087001 SNOMEDCT_US
CHEMBL799 ChEMBL_ID
N7Z035406B UNII
5680 INN_ID
DB01166 DRUGBANK_ID
CHEBI:31401 CHEBI
7148 IUPHAR_LIGAND_ID
2754 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 0054-0028 TABLET 50 mg ORAL ANDA 17 sections
Cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 0054-0044 TABLET 100 mg ORAL ANDA 17 sections
Cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 0093-2064 TABLET 100 mg ORAL ANDA 19 sections
Cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 0093-2065 TABLET 50 mg ORAL ANDA 19 sections
Cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 0185-0123 TABLET 50 mg ORAL ANDA 19 sections
Cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 0185-0223 TABLET 100 mg ORAL ANDA 19 sections
Cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 0615-7713 TABLET 100 mg ORAL ANDA 13 sections
Cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 0615-7716 TABLET 50 mg ORAL ANDA 14 sections
Cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 0615-7747 TABLET 100 mg ORAL ANDA 14 sections
CILOSTAZOL HUMAN PRESCRIPTION DRUG LABEL 1 16590-285 TABLET 100 mg ORAL ANDA 20 sections
cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 50268-176 TABLET 50 mg ORAL ANDA 19 sections
cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 50268-177 TABLET 100 mg ORAL ANDA 19 sections
Cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 54868-5411 TABLET 100 mg ORAL ANDA 13 sections
cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 60505-2521 TABLET 50 mg ORAL ANDA 19 sections
cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 60505-2522 TABLET 100 mg ORAL ANDA 19 sections
Cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 68071-4125 TABLET 100 mg ORAL ANDA 19 sections
Cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 68151-3844 TABLET 50 mg ORAL ANDA 17 sections
Cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 68151-4123 TABLET 100 mg ORAL ANDA 17 sections
Cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 70436-050 TABLET 50 mg ORAL ANDA 19 sections
Cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 70436-051 TABLET 100 mg ORAL ANDA 19 sections
Cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 70518-2200 TABLET 100 mg ORAL ANDA 19 sections
Cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 70518-2208 TABLET 50 mg ORAL ANDA 19 sections
Cilostazol HUMAN PRESCRIPTION DRUG LABEL 1 71610-037 TABLET 100 mg ORAL ANDA 20 sections